Anhui Huaheng Biotechnology (688639) Fundamentals 2026 — P/E 32.0x, Revenue Analysis | SniperIQ
Anhui Huaheng Biotechnology (688639) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥4.0B, trading at ¥15.98 on the SHH. This SniperIQ fundamentals page covers Anhui Huaheng Biotechnology's valuation (P/E 32.0x, P/B 1.5x), profitability (net margin 4.1%), revenue (¥2.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Anhui Huaheng Biotechnology's market cap?
Anhui Huaheng Biotechnology (688639) has a market capitalization of approximately ¥4.0B, trading at ¥15.98 on the SHH. Market cap moves with the live share price.
What is Anhui Huaheng Biotechnology's P/E ratio?
Anhui Huaheng Biotechnology's trailing twelve-month P/E ratio is 32.0x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Anhui Huaheng Biotechnology?
Anhui Huaheng Biotechnology runs a net profit margin of 4.1%, a gross margin of 4.1%, and an operating margin of 4.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Anhui Huaheng Biotechnology generate?
Anhui Huaheng Biotechnology reported revenue of ¥2.9B for fiscal year 2025, with net income of ¥132M and earnings per share (EPS) of 0.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Anhui Huaheng Biotechnology pay a dividend?
Anhui Huaheng Biotechnology offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Anhui Huaheng Biotechnology financially healthy?
Anhui Huaheng Biotechnology carries a debt-to-equity ratio of 0.88x and a current ratio of 1.21x, with a market beta of 0.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Anhui Huaheng Biotechnology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Anhui Huaheng Biotechnology (688639) the key facts are: market cap ¥4.0B, P/E 32.0x, revenue ¥2.9B, 52-week range 14.52-43.6. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Anhui Huaheng Biotechnology's full fundamentals live
Get Anhui Huaheng Biotechnology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.